HyundaiPharm

.	24 2/2


Subject	Joint Development with Forhumantech for a New Drug Candidate
Content	Recently, Hyundai Pharm. signed a contract with ForHumanTech to develop new drug candidate, HFT-401, for Rheumatoid Arthritis. HFT-40 is a synthetic component composed of an existing drug, MTX (methotrexate), to treat Reumatoid Arthritis and PTD (Protein Transduction Domain) to improve permeability on the skin.
Date	2009-03-24


No.	Subject	Date

11	Hyundai Pharmaceutical Co., Ltd. signed ...	2014-01-23

10	Hyundai Pharmaceutical Co., LTD. signed ...	2012-11-01

9	Successfully signed on technology transf...	2012-07-24

8	ATC(Advanced Technology Center) sponsore...	2012-06-19

6	The government’s seal of “innovation”	2012-06-18

4	Hyundai Pharm Chairman Lee won the Silve...	2009-11-27

	Joint Development with Forhumantech for ...	2009-03-24

2	New Release of DIACT Tablet, Oral Hypogl...	2009-02-11

1	Quality Management Award and CCMS certif...	2008-12-20